Thông tin cho nhân viên y tế
Thuốc mới và thông tin từ Drugs.com
- DUBLIN, Nov. 20, 2024 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the…
- Brussels (Belgium), November 20, 2024 – 07:00 (CET) – UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Bimzelx® (bimekizumab-bkzx) for the treatment of adults…
- WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ — Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib) as the first and only menin inhibitor for the treatment of…
- WOBURN, Mass. Nov 14, 2024 – Azurity Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Danziten, the first and only nilotinib with no mealtime restrictions indicated for adult patients with newly…
- WARREN, N.J., Nov. 13, 2024 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) accelerated approval of its gene therapy for the treatment of AADC deficiency, the first-ever gene therapy…
- LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), an early-commercial stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the U.S. Food and Drug Administration…
- WEDNESDAY, Nov. 20, 2024 — For patients with type 2 diabetes and elevated systolic blood pressure, an intensive-treatment strategy is better than a standard-treatment strategy for incidence of major cardiovascular disease events, according to a…
- WEDNESDAY, Nov. 20, 2024 — High cardiorespiratory fitness (CRF) is associated with better cognitive performance and lower dementia risk, according to a study published online Nov. 19 in the British Journal of Sports Medicine. Shuqi Wang, from the…
- WEDNESDAY, Nov. 20, 2024 — The prevalence of high total cholesterol was 11.3 percent among U.S. adults in August 2021 to August 2023, according to a November data brief published by the National Center for Health Statistics. Margaret D. Carroll…
- WEDNESDAY, Nov. 20, 2024 — Teledermoscopy has high accuracy for detecting skin cancers, according to a research letter published online Nov. 9 in the Journal of the American Academy of Dermatology. Jenne P. Ingrassia, from New York Medical College…
- WEDNESDAY, Nov. 20, 2024 — Spinal cord stimulation (SCS) for treatment of chronic pain in the back and/or lower extremities is associated with greater improvements in pain compared with conventional medical management (CMM), according to a review…
- WEDNESDAY, Nov. 20, 2024 — In pregnant women, the oral microbiome is associated with stress and mental health, according to a study published online Nov. 19 in BMJ Mental Health. Ann M. Alex, Ph.D., from Michigan State University in East Lansing…
Thông tin từ The Pharma Letter
- The European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab), from US pharma giant Pfizer.
- Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer.
- Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme.
- Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate.
- A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies.
Thông tin từ BioPharmaDive
- Negative results from a Huntington’s trial add to a calamitous year for Sage, which last month decided to overhaul its research, reconfigure its executive team and lay off a third of its staff.
- Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.
- Built around research by Stanford scientist Carolyn Bertozzi and MIT researcher Jessica Stark, Valora Therapeutics is designing drugs to target glyco-immune checkpoints.
- Analysts see Trump’s victory raising the high-profile legislation’s chances of becoming law. But the realities of a lame duck Congress may cause its timeline for passage to slip back.
- Pfizer will work with Ampersand Biomedicines and Montai Therapeutics to find drugs for obesity and lung cancer, respectively, adding to collaborations it previously formed with other Flagship startups.
- Merck plans to discuss the data with regulators as it lags rivals Roche and Bristol Myers in bringing forward a subcutaneous form of its cancer drug.
Thông tin từ STAT News
- Republicans may target Medicaid for cuts to help fund tax cuts and other GOP priorities
- Kura Oncology has signed a global partnership with Japanese drugmaker Kyowa Kirin to develop and sell an experimental leukemia treatment
- Kennedy, who lacks a background in science or public health, appears intent on remaking the FDA based on assumptions and conspiracy theories
- Proof-of-concept experiments show the device is more efficient than other methods of delivering drugs orally, and more convenient than needles.
- The idea would reduce the role played by the American Medical Association in determining how much doctors get paid
- Today's health news includes Mehmet Oz as Trump's pick to oversee Medicare and Medicaid, rising alcohol deaths, and more.
Thông tin từ Nature Review Drug Discovery
- Nature Reviews Drug Discovery, Published online: 15 November 2024; doi:10.1038/s41573-024-01074-4Recent progress in understanding senescence has spurred interest in the development of approaches that target senescent cells. This Review assesses the current status of senotherapies, such as senolytics and senomorphics, how these approaches can be combined with cancer therapies, and the challenges and opportunities in moving […]
- Nature Reviews Drug Discovery, Published online: 15 November 2024; doi:10.1038/d41573-024-00184-3FDA approves l-amino acid decarboxylase deficiency gene therapy
- Nature Reviews Drug Discovery, Published online: 12 November 2024; doi:10.1038/s41573-024-01060-wDefects in the DNA damage response have been utilized therapeutically for cancer for a decade. This Review analyses the lessons learnt from the development of PARP inhibitors and how these may be applied to new targets to maximize success. Targeting multiple DNA damage response pathways simultaneously […]
- Nature Reviews Drug Discovery, Published online: 08 November 2024; doi:10.1038/d41573-024-00183-4Benchmarking recruitment rates for phase III trials
- Nature Reviews Drug Discovery, Published online: 05 November 2024; doi:10.1038/d41573-024-00181-6JAK inhibition combats adverse skin reaction
- Nature Reviews Drug Discovery, Published online: 05 November 2024; doi:10.1038/d41573-024-00178-1Lundbeck pays US$2.6 billion for Longboard and its lead epilepsy drug